In Vitro Activity of Cefepime-Zidebactam, Ceftazidime-Avibactam, and Other Comparators against Clinical Isolates of Enterobacterales , Pseudomonas aeruginosa, and Acinetobacter baumannii: Results from China Antimicrobial Surveillance Network (CHINET) in 2018

Author:

Yang Yang12,Guo Yan12,Yin Dandan12,Zheng Yonggui12,Wu Shi12,Zhu Demei12,Hu Fupin12ORCID

Affiliation:

1. Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China

2. Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China

Abstract

This study evaluated the in vitro activity of cefepime-zidebactam in comparison with that of ceftazidime-avibactam and other comparators against clinically significant Gram-negative bacillus isolates. A total of 3,400 nonduplicate Gram-negative clinical isolates were collected from 45 medical centers across China in the CHINET Program in 2018, including Enterobacterales ( n  = 2,228), Pseudomonas aeruginosa ( n  = 657), and Acinetobacter baumannii ( n  = 515).

Funder

National Natural Science Foundation of China

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Reference21 articles.

1. Centers for Disease Control and Prevention. 2019. AR threats report. https://www.cdc.gov/drugresistance/biggest-threats.html#carp.

2. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis

3. In vitro activity of the novel monosulfactam BAL30072 alone and in combination with meropenem versus a diverse collection of important Gram-negative pathogens

4. New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship

5. Actavis. 2015. AVYCAZ (ceftazidime-avibactam) for injection for intravenous use. Initial U.S. approval: 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206494s000lbl.pdf.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3